{"prompt": "['9', 'Month 6 phone call ( 3 days)', 'Month 7 phone call ( 3 days)', 'Month 8 Visit ( 3 days)', 'Month 9 phone call (+3 days)', 'Month 10 phone call ( 3 days)', 'Month 11 phone call ( 3 days)', 'Month 12 Visit (end of Part B) ( 3 days)', 'Treatment Arms', 'Part A - 1:1 Randomization (PEMF 42 us : Sham)', 'Part B - open-label PEMF 42 us treatment', 'Efficacy Enppoints', 'Primary Endpoint:', 'Absolute change from baseline in pain intensity as measured', 'by the 11-point, numerical pain rating scale (NPRS) (0-10;', 'where 0=no pain, to 10=worst possible pain) through 4', 'months.', 'Secondary Endpoints:', 'Percentage of patients who have either a 2 point or 30%', 'reduction in NPRS at 4 Months.', 'Time to 30% or 2-point reduction in NPRS, whichever comes', 'first at 4 Months.', 'Change in neuropathy related quality of life (NeuroQoL)', 'between baseline and end of treatment at 4 Months.', 'Changes in Skin Perfusion Pressure from baseline to end of', 'treatment at 4 Months.', 'Changes in Nerve Conduction Studies of Velocity and/or', 'Amplitude between baseline and end of treatment at 4', 'Months.', 'Changes in Quantitative Sensory Testing between baseline', 'and end of treatment at 4 Months.', 'Change in Patient Global Impression at 4 Months.', 'Exploratory Endpoints:', 'Changes in WPAIQ', 'Changes in intraepidermal nerve fiber density (IENFD) at the', 'distal thigh.', 'Changes in IENFD at the distal leg.', 'Evaluation of the NPRS, NCS and NeuroQoI during Part B', 'will be considered exploratory', 'Safety Enppoints', 'Adverse events, serious adverse events', 'Unanticipated adverse device effects', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['10', 'Study Device', 'The study device is the PROVANTR8 Therapy System. The active', 'device will deliver dual field pulsed electromagnetic field energy', 'in the radiofrequency range. The active treatment and inactive', 'sham devices will be identical in appearance and all other', 'physical characteristics in order to maintain the blinding of the', 'treatment. Each device will be identified with a unique kit', 'number.', 'Inclusion/Exclusion', 'Inclusion Criteria', '1. Subject has documented Type 1 or Type 2 diabetes', 'mellitus according to the ADA criteria (Appendix B). 33', '2. Subject has daily pain attributed to symmetrical lower', 'extremity diabetic peripheral neuropathy for at least 6', 'months prior to screening, as confirmed by score of > 6', 'on the Toronto Clinical Neuropathy Scoring System.', \"3. Subjects' average lower extremity pain related to diabetic\", 'peripheral neuropathy over the preceding 24 hours is >4', 'and <9 based on the 11-point NPRS (0-10) at the', 'Screening Visit.', '4. Subject age is greater than or equal to 22 years and less', 'than 80 years of age.', '5. Subject is on stable diabetes treatment which should', 'include medication and/or diet and exercise for at least 3', 'months prior to Screening.', '6. Subject has an HbA1c 10% at Screening or within 3', 'months of Screening.', '7. Subject has not changed their analgesic prescriptions in', 'the preceding one month.', '8. Subject has an ankle-brachial index (ABI) of \">0.8 to <1.3.', 'If the subject has incompressible vessels, a toe brachial', 'index of 0.8 to 1.3 is required. These adequate lower', 'extremity studies are with no documented intermittent', 'claudication.', '9. Subject walks independently with or without assistive', 'devices, and does not require a wheel chair.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['11', '10. Subject is willing and able to give written informed', 'consent and to comply with all parts of the study protocol.', '11. Female subjects must be post-menopausal, surgically', 'sterile, abstinent, or, if of child-bearing potential,', 'practicing (or agreeing to practice) an effective method of', 'birth control if they are sexually active for the duration of', 'the study. Effective methods of birth control include', 'prescription hormonal contraceptives, intrauterine', 'devices, double-barrier methods, and/or male partner', 'sterilization.', '12. Subject can access an internet browser in the home', 'environment or through a smart phone.', 'Enrollment Visit Inclusion Criteria', '1. Average diabetic peripheral neuropathic pain intensity', '(NPRS score) is > 4 and <9 calculated as the mean of the', 'daily NPRS scores for neuropathic pain in the lower', 'extremities over the 7 days preceding the visit.', '2. Subject has completed a minimum of 70% of the ePRO', 'assessments during the run-in period.', 'Exclusion Criteria', '1. Subject has an active, open ulcer on either lower', 'extremity.', '2. Subject has significant peripheral vascular disease', 'defined as absence of more than one-foot pulse per foot', 'and/or ABI <0.7 and >1.3 and/or history of angioplasty,', 'peripheral bypass surgery, or claudication within 6', 'months of the Screening Visit.', '3. Subject has venous insufficiency with an active ulcer as', 'classified by the Venous Insufficiency Classification', 'System of grade C6.', '4. Subject has a history of previous solid organ transplant or', 'severe renal disease (i.e. estimated creatinine clearance', '30 mL/min).', '5. Subject has been diagnosed with a non-diabetic cause of', 'chronic neuropathy (e.g. end stage renal disease,', 'infectious etiology, chemotherapy, drug etiology, alcohol', 'abuse, ingestion of toxic substance, nerve decompression', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}